Compare ACNB & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACNB | PRME |
|---|---|---|
| Founded | 1857 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 595.5M | 536.4M |
| IPO Year | 1994 | 2022 |
| Metric | ACNB | PRME |
|---|---|---|
| Price | $60.84 | $3.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $58.00 | $7.56 |
| AVG Volume (30 Days) | 71.9K | ★ 4.4M |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.00% | N/A |
| EPS Growth | N/A | ★ 18.18 |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $191,821,000.00 | $4,632,000.00 |
| Revenue This Year | $13.18 | $7.06 |
| Revenue Next Year | $1.91 | $47.01 |
| P/E Ratio | $46.85 | ★ N/A |
| Revenue Growth | 45.10 | ★ 55.28 |
| 52 Week Low | $41.03 | $2.67 |
| 52 Week High | $62.07 | $6.94 |
| Indicator | ACNB | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 59.12 | 42.22 |
| Support Level | $48.10 | $3.04 |
| Resistance Level | $61.73 | $3.82 |
| Average True Range (ATR) | 1.38 | 0.34 |
| MACD | -0.04 | -0.09 |
| Stochastic Oscillator | 63.39 | 3.72 |
ACNB Corp is the financial holding company. Through its wholly-owned subsidiaries, it provides a full range of retail and commercial financial services in Pennsylvania and Maryland through its network of community banking offices. It also provides property, casualty, health, life and disability insurance serving personal and commercial clients through offices in Westminster, Maryland, and Gettysburg, Pennsylvania and is licensed to do business. The corporation has two reporting segments; the Banking segment which generates the majority of the revenue from banking and wealth management services, including trust and retail brokerage; and ACNB Insurance Services segment which offers a broad range of property and casualty, life and health insurance to both commercial and individual clients.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.